Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2019 Sep;15(9):499.
doi: 10.1038/s41574-019-0234-2.

T2DM treatment trial results

Claire Greenhill  1
Affiliations
Comment

T2DM treatment trial results

Claire Greenhill. Nat Rev Endocrinol. 2019 Sep.
No abstract available

PubMed Disclaimer

Comment on

References

Original article
    1. Mosenzon, O. et al. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. Lancet Diabetes Endocrinol. https://doi.org/10.1016/S2213-8587(19)30192-5 (2019) - DOI - PubMed
    1. Husain, M. et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa1901118 (2019) - DOI - PubMed
    1. Pieber, T. R. et al. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial. Lancet Diabetes Endocrinol. https://doi.org/10.1016/S2213-8587(19)30194-9 (2019) - DOI - PubMed
    1. Mosenzon, O. et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial. Lancet Diabetes Endocrinol. https://doi.org/10.1016/S2213-8587(19)30180-9 (2019) - DOI - PubMed
    1. Gerstein, H. C. et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet https://doi.org/10.1016/S0140-6736(19)31149-3 (2019) - DOI - PubMed

LinkOut - more resources